A61K 2039/812
Breast
Official title: {Breast}
A61K2039/812 (Breast) appears on 109 US grants and 239 published applications in this corpus.
Search patents in A61K- Granted patents
- 109
- Published applications
- 239
- Assignees
- 125
- Inventors
- 458
- Latest grant
- 8 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 2 |
| 2003 | 0 | 1 |
| 2004 | 0 | 5 |
| 2005 | 0 | 1 |
| 2006 | 0 | 4 |
| 2007 | 0 | 0 |
| 2008 | 1 | 3 |
| 2009 | 0 | 2 |
| 2010 | 0 | 0 |
| 2011 | 1 | 2 |
| 2012 | 1 | 2 |
| 2013 | 1 | 2 |
| 2014 | 2 | 2 |
| 2015 | 2 | 2 |
| 2016 | 2 | 3 |
| 2017 | 2 | 3 |
| 2018 | 4 | 11 |
| 2019 | 6 | 18 |
| 2020 | 11 | 30 |
| 2021 | 7 | 27 |
| 2022 | 13 | 35 |
| 2023 | 16 | 23 |
| 2024 | 12 | 26 |
| 2025 | 20 | 22 |
| 2026 | 5 | 13 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Intracellular delivery of biomolecules to modify immune response8 Sep 2026US 12,728,163 B2Stemcell Technologies Canada Inc.
- Edible plant exosome-like nanovectors for vaccination11 Aug 2026US 12,702,703 B2University of Louisville Research Foundation, Inc.
- Utilizing vaccines to treat cancer and enhance the success rate of cancer immunotherapy19 May 2026US 12,629,413 B2Rush University Medical Center
- Production of exosomes and uses thereof7 Apr 2026US 12,594,344 B2China Medical University
- Cancer neoantigens and their utilities in cancer vaccines and TCR-based cancer immunotherapy3 Mar 2026US 12,565,680 B2The Methodist Hospital System
- Compositions and methods for treatment or prventative treatment of cancer including triple negative breast cancer and/or lung cancer24 Sep 2026US 2026/0284165 A1The Medical College of Wisconsin, Inc.
- Tumor cell vaccines20 Aug 2026US 2026/0240969 A1Neuvogen, Inc.
- Microbial consortium and uses thereof13 Aug 2026US 2026/0232742 A1Biomica Ltd.
- Methods of treating solid tumors driven by her2 alterations with tucatinib in combination with an anti-her2 antibody16 Jul 2026US 2026/0199346 A1Seagen Inc.
- Production of exosomes and uses thereof2 Jul 2026US 2026/0185042 A1China Medical University
Most cited
By later US patents
- Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer84US 7,919,467 B2Immunotope, Inc. · 2011
- Vaccination of cancer patients using tumor-associated antigens mixed with interleukin-2 and granulocyte-macrophage colony stimulating factor59US 5,478,556 A1995
- Compositions, methods, and kits for eliciting an immune response21US 8,425,898 B2Duke University · 2013
- Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof15US 8,268,326 B2The Trustees of the University of Pennsylvania · 2012
- Compositions, methods, and kits for eliciting an immune response14US 9,764,026 B2Duke University · 2017